China Companies’ Out-Licensing Deals ‘Rational’ But Policy-Driven
The acceleration of commercial health insurance was included in national development plans for 2026 released by the Chinese government in the recent “Two Sessions” policy meetings, and appears key for the next generation of innovative drugs to achieve domestic success.
Scrip - March 25, 2026

Use AI As Your Copilot, Not Autopilot, When Navigating Diagnostics
During an ECRI-hosted webinar on AI-enabled diagnostics, a panel of experts discussed the promise and risks that come with the technology for both physicians and patients alike.
Medtech Insight - March 24, 2026

Despite Cheap and Available Drugs, Neurent Spies Opportunity in Chronic Rhinitis Market
Neurent’s Neuromark device, which relieves symptoms of chronic rhinitis via ablation of the vidian nerve, could be well-poised to capture an ever-growing and highly valuable market.
Medtech Insight - March 24, 2026

Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Medtech Insight - March 24, 2026

Indian Medical Device Makers Seek Duty Relief As Gulf Shipping Disruptions Hit Input Costs
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
Medtech Insight - March 24, 2026

Cosmetic Ingredient Review Marks 50 Years Emphasizing Independence, Transparency
Bart Heldreth, Cosmetic Ingredient Review executive director, reflects on the accomplishments of its expert safety panel, which has published safety assessments for more than 7,000 ingredients since CIR’s establishment in 1976.
HBW Insight - March 24, 2026

US FDA Offers Advice On Higher Quality Responses To Form 483 Inspection Findings
FDA aims to prevent poor quality or incomplete responses to Form 483 inspection observations with a new draft guidance describing the structure and content for concise, factual and effective corrective action responses.
HBW Insight - March 24, 2026

Brazil Allows OTC Retail In Supermarkets Via In-Store Pharmacy
Brazil has approved legislation permitting pharmacies to operate within supermarkets, expanding consumer access to OTC medicines while maintaining strict pharmacist oversight and existing safety standards.
HBW Insight - March 24, 2026

Futura Seeking US & EU Approval For New Eroxon Innovation
Futura Medical is seeking OTC medical device approval for ED treatment Eroxon Intense, designed for men who prefer a stronger sensation to the original Eroxon product.
HBW Insight - March 24, 2026

US TikTok Shop Fragrance Sales Surge As Creators Reshape Gen Alpha’s Usage Of Scent
Fragrance intelligence and analytics provider OnScent says US TikTok Shop is on its way to achieving annual sales of $500m.
HBW Insight - March 24, 2026

Cambrex Targets Complex APIs As Outsourcing Demand Rises
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Generics Bulletin - March 24, 2026

Hatch-Waxman Needs Repair To Fight Against Serial Patent Litigations
Serial patent litigations have become a loophole in the Hatch-Waxman Act, disbalancing the scale of innovation and competition, said Jon Potter, executive director of the newly established Coalition Against Pharma Patent Abuse, in an exclusive Generics Bulletin interview.
Generics Bulletin - March 24, 2026

India Deal Strengthens Bio-Thera’s Global Golimumab Strategy
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Generics Bulletin - March 24, 2026

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
In Vivo - March 23, 2026

Practicalities For AI-Enabled Devices As Digital (R)evolution Picks Up Pace
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
In Vivo - March 23, 2026

Chugai’s Narrow Partnering Strategy Means Less Competition
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
In Vivo - March 23, 2026